KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to -$860.0 million.

  • Teva Pharmaceutical Industries' Capital Expenditures rose 80.74% to -$860.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$501.0 million, marking a year-over-year decrease of 60.24%. This contributed to the annual value of -$501.0 million for FY2025, which is 60.24% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Capital Expenditures of -$860.0 million as of Q4 2025, which was up 80.74% from $136.0 million recorded in Q3 2025.
  • In the past 5 years, Teva Pharmaceutical Industries' Capital Expenditures registered a high of $157.0 million during Q1 2022, and its lowest value of -$933.0 million during Q4 2023.
  • Moreover, its 5-year median value for Capital Expenditures was $127.0 million (2022), whereas its average is -$20.8 million.
  • The largest annual percentage gain for Teva Pharmaceutical Industries' Capital Expenditures in the last 5 years was 2213.11% (2023), contrasted with its biggest fall of 75704.23% (2023).
  • Teva Pharmaceutical Industries' Capital Expenditures (Quarter) stood at $153.0 million in 2021, then decreased by 7.19% to $142.0 million in 2022, then tumbled by 757.04% to -$933.0 million in 2023, then rose by 7.07% to -$867.0 million in 2024, then grew by 0.81% to -$860.0 million in 2025.
  • Its Capital Expenditures was -$860.0 million in Q4 2025, compared to $136.0 million in Q3 2025 and $96.0 million in Q2 2025.